Abstract

Background: Site-specific postoperative risk models for localized upper tract urothelial carcinoma (UTUC) are unavailable.

Objective: To create specific risk models for renal pelvic urothelial carcinoma (RPUC) and ureteral urothelial carcinoma (UUC), and to compare the predictive accuracy with the overall UTUC risk model.

Design, setting, and participants: A multi-institutional database retrospective study of 1917 UTUC patients who underwent radical nephroureterectomy (RNU) between 2000 and 2018 was conducted.

Outcome measurements and statistical analysis: A multivariate hazard model was used to identify the prognostic factors for extravesical tract recurrence (EUTR), cancer-specific death (CSD), and intravesical recurrence (IVR) after RNU. Patients were stratified into low-, intermediate-, high-, and highest-risk groups. External validation was performed to estimate a concordance index of the created risk models. We investigated whether our risk models could aid decision-making regarding adjuvant chemotherapy (AC) after RNU.
Results and limitations: The UTUC risk models could stratify the risk of cumulative incidence of three endpoints. The RPUC- and UUC-specific risk models showed better stratification than the overall UTUC risk model for all the three endpoints, EUTR, CSD, and IVR (RPUC: concordance index, 0.719 vs 0.770, 0.714 vs 0.794, and 0.538 vs 0.569, respectively; UUC: 0.716 vs 0.767, 0.766 vs 0.809, and 0.553 vs 0.594, respectively). The UUC-specific risk model can identify the high- and highest-risk patients likely to benefit from AC after RNU. A major limitation was the potential selection bias owing to the retrospective nature of this study.

Conclusions: We recommend using site-specific risk models instead of the overall UTUC risk model for better risk stratification and decision-making for AC after RNU.

Patient summary: Upper tract urothelial carcinoma comprises renal pelvic and ureteral carcinomas. We recommend using site-specific risk models instead of the overall upper tract urothelial carcinoma risk model in risk prediction and decision-making for adjuvant therapy after radical surgery.

© 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Urothelial carcinoma (UC) arises in the renal pelvis, ureters, bladder, or urethra. Upper tract UC (UTUC), including renal pelvic UC (RPUC) and ureteral UC (UUC), accounts for 5–10% of UCs [1]. Radical nephroureterectomy (RNU) with complete removal of the ureteral orifice remains the standard surgical treatment for localized UTUC [2]. UTUC is aggressive, especially in high-grade and high-stage tumors, and has a poor clinical outcome, with a 5-yr cancer-specific survival rate of 66–80% [1,3,4]. Currently, neoadjuvant chemotherapy (NAC) and/or adjuvant chemotherapy (AC) is used to improve the prognosis of UTUC. Studies have demonstrated that RNU with both NAC and AC provides better survival than RNU alone [5]. In the 2021 European Association of Urology guidelines on UTUC, the evidence level of AC was positive level Ib, and platinum-based AC was strongly recommended for patients with pT2 ≤ UTUC or N+ disease, while the evidence level for NAC remains level 2 [6].

In the Peri-Operative chemotherapy versus Surveillance in upper Tract urothelial cancer (POUT) trial, a phase 3 prospective randomized trial, patients with pT2-pT4 N (any) M0 or pT (any) N1–3 M0 UTUC benefited from gemcitabine-platinum combination AC initiated within 90 d after RNU [7]. A subgroup analysis indicated a greater survival benefit from AC in the pN0, pT3/4, and cisplatin regimen groups than in the N+, pT2, and carboplatin regimen groups. The subgroup analyses indicated that not all high-risk populations can benefit from time-consuming and invasive systemic chemotherapy; therefore, clinicians must consider the risk of overtreatment. A more accurate postoperative risk stratification model based on real-world data is required for appropriate decision-making and patient consultation for adjuvant therapy.

In managing UC of the bladder, several clinicopathological parameter–based risk scoring tables are widely used for predicting the short- and long-term probabilities of oncological events [8–10]. Owing to the rarity and heterogeneous biology and behavior of UTUC, there have been limited reports of patient risk stratification using predictive tools [11]. RPUC and UUC have many similarities and are generally considered collectively as UTUC disease sets. However, there are anatomical, biological, and molecular differences, including in the immunological profile and clinical behavior, suggesting two distinct urothelium-derived malignancies [12]. To the best of our knowledge, no study has been conducted to confirm the usefulness of RPUC- and UUC-specific risk stratification models.

This study aimed to develop site-specific risk stratification models for predicting postoperative extracorporeal tract recurrence (EUTR), cancer-specific death (CSD), and intravesical recurrence (IVR) in patients with RPUC or UUC undergoing RNU. Subsequently, the models were externally validated to assess their applicability in patient selection for adjuvant therapy.

2. Patients and methods

2.1. Study cohorts of UTUC and data collection

This retrospective multicenter study was approved by the ethics committee of each participating institute (reference ID: 1298, 1958, 2891, H30-048, and 2018036) of the Nishinihon Uro-Oncology Extensive Collaboration Group framework. Informed consent was obtained from the participants or bereaved families through posters and/or websites using the opt-out method [13].

We reviewed the medical charts of 2447 consecutive patients with UTUC who underwent RNU and were diagnosed with UC between 2000 and 2018 at six institutions across Western Japan (Fig. 1). Of the 2447 patients, 342 (14%) were excluded because of critical missing data. One of the study aims was to develop risk stratification models for AC; therefore, 188 patients (7.7%) who received NAC were excluded. The methods used for lymph node dissection was inconsistent among surgeons and hospitals, and changed over time. In general, a template-based dissection that was dependent on tumor location [14] was performed in our collaborative academic hospitals for UTUC patients with suspected tumors ≥T2 or clinically node-positive tumors. The 1307 patients initially registered from four institutions were used as the development dataset, and another independent dataset of 610 patients, additionally registered from two institutions, was used for external validation.
2.2. Follow-up and endpoints

The standard protocol was generally used for the follow-up after RNU: cystoscopy, urinary cytology, and abdominopelvic and chest computed tomography (CT) are performed every 3 mo for 2 yr, every 6 mo until 5 yr, and then yearly. This study evaluated three endpoints: EUTR, CSD, and IVR. EUTR was defined as any recurrence, excluding IVR and contralateral UTUC. While IVR is generally considered non–life threatening, EUTR includes life-threatening events such as local recurrence in soft tissue, regional lymph node involvement, and metastatic disease. Other-cause deaths before EUTR, CSD, and IVR were analyzed as competing risks. Patients who were alive without events were censored at the dates of the last follow-up cystoscopy for IVR, last imaging examination for EUTR, and last visit for CSD.

2.3. Identification of prognostic factors and development of new risk tables

To develop multiple risk stratification models—“the Japanese Nishinioh uro-onCology Extensive collaboration group (J-NICE) risk models”, first, univariate and multivariate Fine and Gray subdistribution hazard models were applied for all endpoints to assess the prognostic impact of clinicopathological factors in our cohort [15]. Second, the best combination of variable subsets was selected from all the variable combinations according to the Akaike information criterion [16]. Third, the score allocated to each selected prognostic factor was derived from rounding up regression coefficients of the final multivariate models. Fourth, the total score corresponding to a given patient’s factors was summed up. Fifth, patients were divided into four groups according to their total score.

2.4. External validation using an independent dataset

External validation was conducted using an independent dataset of 610 patients with UTUC treated in two other hospitals. The patients were stratified into four groups according to the J-NICE risk table. The model performance was assessed with respect to calibration and discrimination. The calibration plot was graphically generated to examine the relationship between the observed cumulative incidence estimates and the predicted probabilities for each risk group. The stratification ability (discrimination) for events in the J-NICE risk tables was evaluated using the concordance index (c-index) for the three endpoints.

2.5. Statistical analysis

The statistical software EZR, which is based on the open-source R statistical software (version 3.6.1; R Foundation for Statistical Computing, Vienna, Austria), and PRISM software version 9 (GraphPad Software, Inc., San Diego, CA, USA) were used for statistical analyses and data visualization, respectively. We used Mann-Whitney U test for continuous
variables and the chi-square test to compare the proportions of categorical variables between the groups. Survival packages were used to calculate c-index for our study. Statistical significance was set at \( p < 0.05 \).

3. Results

3.1. Development of risk scoring tables for three endpoints

Clinicopathological characteristics of the patients are presented in Supplementary Table 1. Among the 1917 (total) patients, the pathological N category data were available for 1319 (72%) patients undergoing lymph node dissection. Pathologically positive lymph node involvement was detected in 172 (9.0%) patients. None of the patients underwent early postoperative intravesical chemotherapy. In the development dataset (\( n = 1307 \)), during follow-up after RNU (median, 37.1 mo; interquartile range [IQR] 16.6–69.0), 362 (27.7%) and 470 (36.0%) patients experienced EUTR and IVR, respectively. A total of 250 (19.1%) patients died of UC and 87 (6.7%) died of other causes (competing risks). Prognostic factors for each endpoint in the UTUC development cohort (\( n = 1307 \)), RPUC development cohort (\( n = 766 \)), and UUC development cohort (\( n = 541 \)) were identified using univariate and subsequent multivariate analyses (Supplementary Tables 2–4). Each patient’s score was calculated based on the factor coefficients in the multivariate model, and Table 1 – The J-NICE risk tables for calculating risk scores for extra-urinary tract recurrence, cancer-specific death, and intravesical recurrence in the UTUC patients undergoing radical surgery:

| Factors                              | Overall UTUC risk model | RPUC-specific risk model | UUC-specific risk model |
|--------------------------------------|-------------------------|--------------------------|-------------------------|
|                                      | EUTR (6)               | CSD (5)                  | IVR (6)                 |
|                                      | EUTR (4)               | CSD (3)                  | IVR (4)                 |
|                                      | EUTR (3)               | CSD (6)                  | IVR (5)                 |
| Sex                                  |                        |                          |                         |
| Male                                 | 1                      | 1                        | 0                       |
| Female                               | 0                      | 0                        | 1                       |
| Location of main tumor               |                        |                          |                         |
| Renal pelvis                         | 0                      | 0                        | 0                       |
| Upper ureter                         | 0                      | 0                        | 0                       |
| Middle ureter                        | 1                      | 1                        | 1                       |
| Lower ureter                         | 1                      | 0                        | 1                       |
| Multifocality                        |                        |                          |                         |
| Solitary                             | 0                      | 0                        | 0                       |
| Multiple                             | 1                      | 1                        | 1                       |
| Hydrounephrosis                      |                        |                          |                         |
| No                                   | 1                      | 1                        | 1                       |
| Yes                                  | 0                      | 0                        | 0                       |
| Baseline hemoglobin                  |                        |                          |                         |
| ≥ LLN                                |                        |                          |                         |
| < LLN                                | 2                      | 1                        |                         |
| Baseline NLR                         |                        |                          |                         |
| < 3.0                                | 0                      | 0                        | 0                       |
| ≥ 3.0                                | 1                      | 1                        | 1                       |
| Clinical N category                  |                        |                          |                         |
| N0                                   | 0                      | 0                        | 0                       |
| N+                                   | 2                      | 3                        | 3                       |
| Pathological T category              |                        |                          |                         |
| Ta/Tis                               | 0                      | 0                        | 0                       |
| T1                                   | 1                      | 1                        | 1                       |
| T2                                   | 2                      | 2                        | 2                       |
| T3                                   | 3                      | 3                        | 3                       |
| T4                                   | 4                      | 4                        | 4                       |
| Tumor grade (WHO 2004)               |                        |                          |                         |
| Low grade                            | 0                      | 0                        | 0                       |
| High grade                           | 1                      | 2                        | 1                       |
| Carcinoma in situ                    | 1                      | 1                        | 1                       |
| Lymphovascular invasion              |                        |                          |                         |
| No                                   | 0                      | 0                        | 0                       |
| Yes                                  | 2                      | 2                        | 2                       |
| Total scores                         | 0–11                   | 0–10                     | 0–7                     |
| Risk stratification                  |                        |                          |                         |
| Low-risk                             | 0–2                    | 0–2                      | 0–1                     |
| Intermediate-risk                    | 2–4                    | 2–3                      | 2–3                     |
| Highest-risk                         | 6–8                    | 5–7                      | 4–5                     |
| CSD = cancer-specific death; EUTR = extraurinary tract recurrence; IVR = intravesical recurrence; J-NICE = Japanese Nishinomiya uro-oncology extensive collaboration group; LLN = lower limit of the normal; NLR = neutrophil lymphocyte rate; RPUC = renal pelvic urothelial cancer; UTUC = upper urinary tract cancer; UUC = ureteral urothelial carcinoma; WHO = World Health Organization. Parentheses indicate the total number of patients.

The allocated scores were determined by rounding up regression coefficients shown in Supplementary Tables 2–4. For example, prognostic factors with regression coefficients >0 and ≤1 were allocated 1 point, prognostic factors with regression coefficients >1 and ≤2 were allocated 2 points, prognostic factors with regression coefficients >2 and ≤3 were allocated 3 points, and prognostic factors with regression coefficients >3 were allocated 4 points. On the contrary, 1 or 2 points were allocated to the counterparts when regression coefficients were >–1 and <0 or >–2 and <–1, respectively.
patients were divided into four groups according to the total J-NICE score: low-, intermediate-, high-, or highest-risk group (Table 1). Supplementary Table 5 shows the actual probabilities after RNU at 2, 5, and 10 yr and their 95% CIs according to patient risk.

3.2. External validation using an independent dataset

We conducted external validation on an independent data-set of patients with UTUC. The development and validation sets showed no significant difference in the location of the main tumor and pathological T category, whereas clinical N category, tumor grade, baseline hemoglobin, and baseline neutrophil lymphocyte ratio (NLR) showed significant differences (Supplementary Table 1). In the validation dataset (n = 610), during follow-up after RNU (median, 34.4 mo; IQR 16.8–71.3), 203 (33.3%) and 245 (40.2%) patients experienced EUTR and IVR, respectively. In all, 150 (24.6%) patients died of UC and 74 (12.1%) died of other causes (competing risks). The J-NICE overall UTUC risk models could stratify the risks of cumulative incidence of EUTR, CSD, and IVR for the development (data not shown) and validation datasets (Fig. 2).

Next, we investigated whether site-specific risk models showed better stratification of the cumulative incidence risk than the overall UTUC risk model. A comparison of the accuracy for predicting the outcomes in the RPUC validation set (n = 327) between the overall UTUC risk model and each specific risk model revealed better stratification for all three endpoints: EUTR (c-index, 0.719 vs 0.770), CSD (0.714 vs 0.794), and IVR (0.538 vs 0.569) in the RPUC model (Fig. 3), and EUTR (0.716 vs 0.767), CSD (0.66 vs 0.809), and IVR (0.553 vs 0.594) in the UUC model (Fig. 4). Calibration plots of the relationships between the actual 1-, 2-, 5-, and 10-yr cumulative incidences for three endpoints and the predicted probabilities for each risk group using the external validation set are shown in Supplementary Figures 1–3, demonstrating that the predicted EUTR and CSD rates from the risk table correlated closely with the actual observations of survival in the external validation set. Thus, the external validation suggests that the site-specific risk models may better fit the real-world clinical practice of UTUC risk assessment than the overall UTUC risk model.

3.3. Identification of patients who are likely to benefit from AC

To identify patients at a high-risk of UTUC who are likely to benefit from AC after RNU, we extracted a cohort of patients who met all the inclusion criteria and none of the exclusion criteria of the POUT trial referring to the trial identifier NCT01993979 of ClinicalTrials.gov [7]. We paid special attention to pT category, pN category, variant histology, hematological profile, liver function tests, postoperative renal function (glomerular filtration rate), and World Health Organization performance status. Of 1917 patients, 1028 (53.6%) including 595 with RPUC and 433 with UUC were defined as the POUT-eligible patients. We compared the outcomes between AC-treated and surveillance patients among 1028 POUT-eligible patients stratified by the J-NICE risk models. Figure 5 summarizes the subgroup analyses for EUTR and CSD with patients stratified by the J-NICE risk models, revealing that the UUC-specific risk model could help stratify high- and highest-risk patients who are likely to benefit from AC after RNU (Fig. 5). AC provided significant benefit for EUTR and CSD in the highest-risk group stratified by the overall UTUC risk model.
4. Discussion

Much effort has been made to create a universal risk stratification tool for the management of UTUC that could aid in identifying candidates for perioperative therapy, such as neoadjuvant or adjuvant therapy. The novelty of our study includes the creation of RPUC- and UUC-specific risk models, separately from the overall UTUC risk model. Almost all currently available risk stratification models were created and developed by incorporating both RPUC and UUC into a single risk model [11]. Bladder UC, RPUC, and UUC commonly arise from the urothelial mucosa and have many similarities, but also have many differences [12,17,18]. We previously demonstrated that the immunological profile of the tumor microenvironment differs significantly between UCs arising from the renal pelvis and ureter [12]. This led us to consider bladder UC, RPUC, and UUC as disparate triplets biologically and clinically.

To create the risk scoring tables, we evaluated several patient- and tumor-related factors that could influence outcomes and prognosis. Common risk factors in the RPUC- and UUC-specific risk models included sex, multifocality, pathological T category, and lymphovascular invasion. Notably, there were factors that were not common to the two risk
models. For example, tumor grade and clinical N category are included in the RPUC-specific but not in the UUC-specific risk model. The presence of hydronephrosis, baseline hemoglobin, baseline NLR, and presence of carcinoma in situ were included in the UUC-specific but not in the RPUC-specific risk model. This discrepancy suggests that a site-specific risk model could provide better stratification than the overall UTUC risk model. The comparison using the external validation dataset revealed that both site-specific risk models showed higher c-indices on all endpoints and provide better risk stratification than the overall UTUC risk model (Fig. 3 and 4), suggesting that our risk model better fits clinical practice of UTUC risk assessment. All six noncommon factors—tumor grade, clinical N category, presence of hydronephrosis, baseline hemoglobin, baseline NLR, and presence of CIS—have been reported as significant risk factors for patients with UTUC undergoing RNU. Although these factors contribute to oncological outcomes in overall UTUC cohorts, the weighting may be unbalanced between two subsets. The EORTC [8] and CUETO [9] risk tables are widely used in the clinical management of non–muscle-invasive bladder cancer.
Fig. 5 – An analysis of extraurinary tract recurrence and cancer-specific death in risk subgroups stratified the J-NICE risk models in the POUT-eligible patients. The POUT-eligible patients were defined as those who met all the inclusion criteria and none of the exclusion criteria of the POUT trial. A total of 1028 POUT-eligible patients were stratified into low-, intermediate-, high-, and highest-risk groups according to the total score, as shown in Table 1. The Fine and Gray subdistribution hazard models were used to calculate HR and 95% CI. AC = adjuvant chemotherapy; CI = confidence interval; HR = hazard ratio; J-NICE = Japanese Nishinon Uro-onCology Extensive Collaboration Group; POUT = Peri-Operative chemotherapy versus surveillance in upper Tract urothelial cancer; RPUC = RPUC = renal pelvic urothelial carcinoma; UTUC = upper urinary tract carcinoma; UUC = ureteral urothelial carcinoma.
cancer. Given that no risk stratification table has widely been accepted yet in the management of UTUC [11], robustness of risk stratification should be improved gradually to suit real-world clinical practice; this indicates the need for more accurate and user-friendly risk stratification models. As expected, the stratification ability (discrimination) for events in the site-specific J-NICE risk tables work better than overall UTUC risk tables based on the c-index for the three endpoints in the external validation. We believe that accurate and user-friendly J-NICE risk tables will be used more widely in the clinical practice of UTUC after sufficient external validation.

Although the POUT trial showed a great impact of AC on disease-free and metastasis-free survival, chemotherapy-induced acute toxicity and a transient negative impact on patient-reported quality of life have been reported [7]. Zhang et al [24] reported that patient-reported anxiety and depression increased during AC in patients with muscle-invasive bladder cancer after radical cystectomy. The negative effects of AC should not be ignored. Owing to the heterogeneous nature of UTUC and the overtreatment risk of perioperative chemotherapy, decision-making for proper therapeutic options is challenging. In this study, we expected that our site-specific risk models could stratify the POUT-eligible patients who are likely to benefit from AC. Theoretically, AC could improve clinical outcomes by reducing the viability of residual and circulating cancer cells after RNU. Our findings prove that patients with J-NICE high- and highest-risk UTUC, especially those with UUC, have possible residual and circulating cancer cells (Fig. 5). Patients with low- and intermediate-risk UTUC might be surveyed postoperatively without AC to avoid treatment-related adverse events and reduce medical costs. The latest evidence demonstrates that RNU with AC for advanced UTUC provides a survival benefit compared with RNU alone [5,6,25]. A recent clinical trial, Checkmate 274, demonstrated the positive role of adjuvant nivolumab in high-risk muscle-invasive UC after radical surgery [26]. Of the enrolled patients, 560 (79%) had bladder cancer, 96 (14%) had RPUC, and 53 (7.5%) had UUC. The subgroup analysis demonstrated that adjuvant nivolumab provided a disease-free survival benefit only in bladder cancer (hazard ratio [HR], 0.62; 95% CI 0.49–0.78), while no significant benefit was observed in RPUC (HR 1.16; 95% CI 0.63–2.13) and UUC (HR 1.55, 95% CI 0.70–3.45). Platinum-based chemotherapy remains the gold-standard adjuvant option for high-risk UTUC.

This study has several limitations. First, the retrospective study design has an inherent potential for selection bias, and the decision criteria for the implementation of NAC/AC, chemotherapy regimen, timing of changing the treatment, and interval of radiographic evaluation were dependent on the institutional protocol and the physician’s discretion. The cohort was derived from multiple institutions, which may have introduced inconsistencies in surgical skills, timing of ureteral ligation, clinical interpretation, and pathological diagnoses. Second, the treatment strategy; modality, especially approval of gemcitabine plus platinum combination chemotherapy and advent of immune checkpoint inhibitors; and surgical skill change over time may influence outcomes. A substantial population (28%) of patients did not undergo lymph node dissection. Moreover, the number of dissected lymph nodes and the data pertaining to positive surgical margins were not available. Third, the cohort did not include patients undergoing kidney-sparing treatment, such as segmental nephroureterectomy and endoscopic laser ablation, which are currently recommended for low-grade, solitary, and small tumors. Fourth, statistical power may be limited because of the small number of patients and events in some subgroups. Fifth, this study did not analyze molecular biomarkers such as PD-1 or PD-L1 immunostaining and other possible biological factors, which may have strengthened the predictive power of our risk models. Further research is required to consolidate our findings and confirm the molecular aspects influencing the clinical effects of AC.

5. Conclusions

To the best of our knowledge, this is the first study to develop an RPUC-specific and a UUC-specific risk model, separately from the overall UTUC risk model. Future external validation with more extensive and diversified patient cohorts is vital to confirm real-world clinical impact.

**Author contributions:** Makito Miyake had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Miyake, Fujimoto.

**Acquisition of data:** Nishimura, Matsumoto, Fujiiwara, Komura, Inamoto, Yasumoto, Shiina, Yonemori, Enokida, Fukuhara, Yoshida, Kinoshita.

**Analysis and interpretation of data:** lida, T. Inoue, Fujii.

**Drafting of the manuscript:** Miyake.

**Critical revision of the manuscript for important intellectual content:** Matsuyama, Fujimoto.

**Statistical analysis:** lida, T. Inoue.

**Obtaining funding:** Miyake, Fujimoto.

**Administrative, technical, or material support:** Fujii.

**Supervision:** Azuma, Matsuda, K. Inoue, Nakagawa.

**Other:** None.

**Financial disclosures:** Makito Miyake certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

**Funding/Support and role of the sponsor:** This research was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI grant numbers 1592057 (Kiyohide Fujimoto), 16K20159 (Makito Miyake), and 26861290 (Kiyohide Fujimoto), and Fiscal Years 2015–2016 Nara Medical University Grant-in-Aid for the Collaborative Research Projects (Kiyohide Fujimoto and Makito Miyake).

**Data sharing:** Data are available for bona fide researchers who request it from the authors.
Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.euros.2022.05.004.

References

[1] Miyake M, Tatsumi Y, Fujimoto K, et al. Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma in the last two decades: a retrospective analysis based on a multicenter collaborative study. Jpn J Clin Oncol 2016;46:1148–55.

[2] Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 2021;79:62–70.

[3] David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM. European Association of Urology. Upper urinary tract urothelial cell carcinoma. Arnhem, The Netherlands: EAU Guidelines Office; presented at the EAU Annual Congress Amsterdam, 2022 https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/#7.

[4] Zigeuner R, Shariat SF, Margulis V, et al. Tumor necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 2010;57:575–81.

[5] Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol 2021;79:635–54.

[6] European Association of Urology. Upper urinary tract urothelial cell carcinoma. Arnhem, The Netherlands: EAU Guidelines Office; presented at the EAU Annual Congress Amsterdam, 2022 https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/#7.

[7] Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 2020;395:1268–77.

[8] Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–75.

[9] Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette–Guerin: the CUETO scoring model. J Urol 2009;182:2195–203.

[10] Miyake M, Matsuyama H, Teramukai S, et al. A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables. Int J Clin Oncol 2020;25:1364–76.

[11] Kardoust Parizi M, Glybochko PV, Enikeev D, et al. Risk stratification of upper tract urothelial carcinoma: a review of the current literature. Expert Rev Anticancer Ther 2019;19:503–13.

[12] Miyake M, Hori S, Owari T, et al. Clinical impact of tumor-infiltrating lymphocytes and PD-L1-positive cells as prognostic and predictive biomarkers in urological malignancies and retroperitoneal sarcoma. Cancers (Basel) 2020;12:3153.

[13] Vellinga A, Cormican M, Hanahoe B, Bennett K, Murphy AW. Opt-out as an acceptable method of obtaining consent in medical research: a short report. BMC Med Res Methodol 2011;11:40.

[14] Kondo T, Hashimoto Y, Kobayashi H, et al. Template-based lymphadenectomy in uterine carcinoma of the upper urinary tract: impact on patient survival. Int J Urol 2010;17:848–54.

[15] Fine JP, Gray RJ. A proportional hazards model for subdistribution of competing risk. J Am Stat Assoc 1999;94:496–509.

[16] Akaike H. Information theory and an extension of the maximum likelihood principle. In: Proceedings of 2nd international symposium information theory. Budapest, Hungary: Akademia Kiado; 1973. p. 267–81.

[17] Green DA, Rink M, Xylinas E, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013;189:1214–21.

[18] Yates DR, Catto JW. Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: How molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumors. World J Urol 2013;31:21–9.

[19] Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224–33.

[20] Miyake M, Marugami N, Fujisawa Y, et al. Down-grading of ipsilateral hydrenephrosis by neoadjuvant chemotherapy correlates with favorable oncological outcomes in patients undergoing radical nephroureterectomy for ureteral carcinoma. Diagnostics (Basel) 2019;10:10.

[21] Inamoto T, Matsuyama H, Iibuki N, et al. Risk stratification by means of biological age-related factors better predicts cancer-specific survival than chronological age in patients with upper tract urothelial carcinoma: a multi-institutional database study. Ther Adv Urol 2018;10:403–10.

[22] Itami Y, Miyake M, Tatsumi Y, et al. Preoperative predictive factors focused on inflammation-, nutrition-, and muscle-status in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy. Int J Clin Oncol 2019;24:533–45.

[23] Inamoto T, Matsuyama H, Iibuki N, et al. Biological behavior and long-term outcomes of carcinoma in situ in upper urinary tract managed by radical nephroureterectomy. J Urol 2018;199:933–9.

[24] Zhang Y, Wang Y, Song B, Li H. Patients’ self-report anxiety, depression and quality of life and their predictive factors in muscle invasive bladder cancer patients receiving adjuvant chemotherapy. Psychol Health Med 2020;25:190–200.

[25] Aziz A, Dobruch J, Hendriksens K, et al. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. World J Urol 2017;35:1401–7.

[26] Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:2102–14.